Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | MMP1 | P03956 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 1/20 | 0.53 |
| ▸ | MMP13 | P45452 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MET | P08581 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2361629 | 0.81 | GAA (0.52) | KMT2AMEN1ALDH1A1PKMPOLB | |
| SCHEMBL2360974 | 0.79 | ALDH1A1 (0.84) | KMT2AMEN1ALDH1A1PKMPOLB | |
| SCHEMBL2039879 | 0.77 | KMT2A (1.00) | KMT2AMEN1ALDH1A1PKMPOLB | |
| SCHEMBL11566827 | 0.77 | KMT2A (1.00) | KMT2AMEN1ALDH1A1PKMPOLB | |
| SCHEMBL30446303 | 0.77 | KMT2A (1.00) | KMT2AMEN1ALDH1A1PKMPOLB | |
| SCHEMBL4070583 | 0.76 | ALDH1A1 (0.69) | KMT2AMEN1ALDH1A1PKMPOLB | |
| SCHEMBL5347059 | 0.76 | ALDH1A1 (0.97) | KMT2AMEN1ALDH1A1PKMPOLB | |
| SCHEMBL237684 | 0.75 | KMT2A (0.73) | KMT2AMEN1ALDH1A1PKMPOLB | |
| SCHEMBL18794812 | 0.75 | ALDH1A1 (0.69) | KMT2AMEN1ALDH1A1PKMPOLB | |
| SCHEMBL28137833 | 0.75 | ALDH1A1 (1.00) | KMT2AMEN1ALDH1A1PKMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910383-B1 | BENZODIAZEPINE DERIVATIVES AND USES THEREOF IN MEDICAL FIELD | UNIV ROMA (IT) | 2009-09-16 | — | — | EP | disclosed |
| US-20080249080-A1 | Benzodiazepine Derivatives and Uses Thereof on Medical Field | UNIVERSITA' DEGLI STUDI DI ROMA,,TOR VERGATA" (IT) | 2008-10-09 | — | — | US | disclosed |
| US-20080249080-A1 | Benzodiazepine Derivatives and Uses Thereof on Medical Field | UNIVERSITA' DEGLI STUDI DI ROMA,,TOR VERGATA" (IT) | 2008-10-09 | — | — | US | disclosed |
| WO-2007015280-A1 | BENZODIAZEPINE DERIVATIVES AND USES THEREOF IN MEDICAL FIELD | UNIVERSITA' DEGLI STUDI DI ROMA 'TOR VERGATA' (IT) | 2007-02-08 | — | — | WO | disclosed |
| EP-1011652-A4 | NOVEL DIARYLSULFONE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS | UNIV THE SCIENCES IN PHILADELP (US) | 2004-12-22 | — | — | EP | disclosed |
| US-6303630-B1 | TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTION BYADMINISTERING TO A HUMAN DIARYLSULFONE COMPOUND | UNIVERSITY OF THE SCIENCES IN PHILADELPHIA | 2001-10-16 | — | — | US | disclosed |
| EP-1011652-A1 | NOVEL DIARYLSULFONE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS | University of the Sciences in Philadelphia (US) | 2000-06-28 | — | — | EP | disclosed |
| US-6063790-A | TREATMENT OF AIDS | UNIVERSITY OF THE SCIENCES IN PHILADELPHIA (US) | 2000-05-16 | — | — | US | disclosed |
| WO-1999006037-A1 | NOVEL DIARYLSULFONE NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS | UNIVERSITY OF THE SCIENCES IN PHILADELPHIA (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249080-A1 | Benzodiazepine Derivatives and Uses Thereof on Medical Field | CNR1, CNR2, CBR3 | KMT2A 2396/4885MEN1 3141/4885ALDH1A1 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.